Telix Submits NDA for New Prostate Cancer Imaging Agent
The Company believes this will further expand the availability, distribution and scheduling flexibility of PSMA-PET imaging.
- The Company believes this will further expand the availability, distribution and scheduling flexibility of PSMA-PET imaging.
- PSMA-PET imaging represents a major advancement in prostate cancer management and in the U.S. has replaced conventional imaging methods (bone scan, CT scan) as the standard of care after initial diagnosis and biochemical recurrence6.
- Despite this major medical advancement, only a relatively small fraction of the 3.4 million men living with prostate cancer in America have undergone a PSMA-PET imaging scan7,8.
- Mike Crosby, Founder and CEO Veterans Prostate Cancer Awareness (VPCa) stated, “Even in some of the most populous U.S. states, access to PSMA-PET imaging can be highly variable.